Zydus Lifesciences Limited has informed the Exchange regarding 'Reporting of violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015'.
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences reported that Mr. Dilip Tulsiyani, General Manager – Corporate Accounts (a Designated Person under insider trading rules), inadvertently executed a contra trade by selling 10 equity shares of the company on June 2, 2025, valued at Rs. 9,240. This is treated as a violation of Regulation 9 read with Clause 10 of Schedule B of SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's Code of Conduct. The company issued a warning letter, and Mr. Tulsiyani submitted an apology admitting the trade was unintentional. The small profit of Rs. 60 from the contra trade has been transferred online to the IEPF account. There are no prior violations on record.
This is a very minor, procedural compliance lapse by one mid-level employee involving just 10 shares, with no indication of trading based on unpublished price-sensitive information. Shareholders are unlikely to see any meaningful impact on the stock price or company fundamentals, as the matter has been internally resolved with a warning and disgorgement of the small profit.